drugset / Trial / NCT01253551

VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

NCT01253551

RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to confirm the absence of a clinically relevant interaction between telaprevir and raltegravir at steady-state.Telaprevir is being investigated for the treatment of chronic hepatitis C virus infection, and raltegravir is used to treat HIV infection.

Timeline

Start
2010-12
Primary completion
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltegravir Other / unclassified 400 mg Oral
Subject Telaprevir Small molecule 750 mg Oral